Zuben E Sauna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1534145/publications.pdf

Version: 2024-02-01

89 papers	8,621 citations	81743 39 h-index	56606 83 g-index

93 all docs	93 docs citations	93 times ranked	11955 citing authors

#	Article	IF	Citations
1	HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset. Frontiers in Medicine, 2021, 8, 663396.	1.2	4
2	Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16. Frontiers in Immunology, 2021, 12, 692157.	2.2	2
3	Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4+ T-cells. Nature Communications, 2021, 12, 5090.	5.8	12
4	Secondary failure: immune responses to approved protein therapeutics. Trends in Molecular Medicine, 2021, 27, 1074-1083.	3.5	9
5	Mathematical model of a personalized neoantigen cancer vaccine and the human immune system. PLoS Computational Biology, 2021, 17, e1009318.	1.5	7
6	Endotoxin contamination in commercially available Cas9 proteins potentially induces T-cell mediated responses. Gene Therapy, 2021, , .	2.3	2
7	Quantitative HLAâ€classâ€II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 201-216.	1.9	3
8	Clinical manifestation of hemophilia A in the absence of mutations in the F8 gene that encodes FVIII: role of microRNAs. Transfusion, 2020, 60, 401-413.	0.8	22
9	Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis. Cancers, 2020, 12, 2784.	1.7	14
10	Further Evidence That MicroRNAs Can Play a Role in Hemophilia A Disease Manifestation: F8 Gene Downregulation by miR-19b-3p and miR-186-5p. Frontiers in Cell and Developmental Biology, 2020, 8, 669.	1.8	8
11	A Foundational Study for Normal F8-Containing Mouse Models for the miRNA Regulation of Hemophilia A: Identification and Analysis of Mouse miRNAs that Downregulate the Murine F8 Gene. International Journal of Molecular Sciences, 2020, 21, 5621.	1.8	4
12	Modified aptamers as reagents to characterize recombinant human erythropoietin products. Scientific Reports, 2020, 10, 18593.	1.6	6
13	Editorial: Immunogenicity of Proteins Used as Therapeutics. Frontiers in Immunology, 2020, 11, 614856.	2.2	14
14	Role of microRNAs in Hemophilia and Thrombosis in Humans. International Journal of Molecular Sciences, 2020, 21, 3598.	1.8	27
15	TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity. AAPS Journal, 2019, 21, 96.	2.2	13
16	Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies. Scientific Reports, 2019, 9, 15449.	1.6	38
17	Fc-Fusion Drugs Have FcÎ³R/C1q Binding and Signaling Properties That May Affect Their Immunogenicity. AAPS Journal, 2019, 21, 62.	2.2	15
18	TCPRO: An In-Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity. Biophysical Journal, 2019, 116, 563a.	0.2	0

#	Article	IF	Citations
19	Translational and transcriptional responses in human primary hepatocytes under hypoxia. American Journal of Physiology - Renal Physiology, 2019, 316, G720-G734.	1.6	7
20	Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. Blood Advances, 2019, 3, 1429-1440.	2.5	20
21	Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue. Blood Advances, 2019, 3, 2668-2678.	2.5	7
22	SampPick: Selection of a Cohort of Subjects Matching a Population HLA Distribution. Frontiers in Immunology, 2019, 10, 2894.	2.2	6
23	Immunogenicity assessment during the development of protein therapeutics. Journal of Pharmacy and Pharmacology, 2018, 70, 584-594.	1.2	94
24	Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins. Trends in Biotechnology, 2018, 36, 1068-1084.	4.9	79
25	Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population. Molecular Therapy - Methods and Clinical Development, 2018, 10, 105-112.	1.8	181
26	Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. Science Translational Medicine, 2017, 9, .	5.8	57
27	Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B. Journal of Medical Genetics, 2017, 54, 338-345.	1.5	66
28	Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model. Journal of Thrombosis and Haemostasis, 2017, 15, 721-734.	1.9	6
29	Recent advances in (therapeutic protein) drug development. F1000Research, 2017, 6, 113.	0.8	348
30	The intron-22â€“inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics. Blood, 2015, 125, 223-228.	0.6	22
31	Genetic determinants of immunogenicity to factorIXduring the treatment of haemophilia B. Haemophilia, 2015, 21, 210-218.	1.0	18
32	Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene. PLoS ONE, 2015, 10, e0132433.	1.1	22
33	Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery. Nucleic Acids Research, 2015, 43, 5699-5707.	6.5	97
34	Personalized approaches to the treatment of hemophilia A and B. Personalized Medicine, 2015, 12, 403-415.	0.8	2
35	Fc fusion as a platform technology: potential for modulating immunogenicity. Trends in Biotechnology, 2015, 33, 27-34.	4.9	135
36	Pharmacogenetics and the Immunogenicity of Protein Therapeutics. Journal of Interferon and Cytokine Research, 2014, 34, 931-937.	0.5	10

#	Article	IF	Citations
37	Single-nucleotide variations defining previously unreportedADAMTS13haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family. British Journal of Haematology, 2014, 165, 154-158.	1.2	5
38	Exposing synonymous mutations. Trends in Genetics, 2014, 30, 308-321.	2.9	272
39	AptaCluster â€“ A Method to Cluster HT-SELEX Aptamer Pools and Lessons from Its Application. Lecture Notes in Computer Science, 2014, 8394, 115-128.	1.0	71
40	Higher-Order Structure and Protein Aggregate Characterization of Protein Therapeutics: Perspectives from Good Manufacturing Practices and Regulatory Guidance. , 2013, , 261-281.		1
41	Endogenous factor VIII synthesis from the intron 22â€“inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nature Medicine, 2013, 19, 1318-1324.	15.2	59
42	Building better drugs: developing and regulating engineered therapeutic proteins. Trends in Pharmacological Sciences, 2013, 34, 534-548.	4.0	77
43	Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment. PLoS Computational Biology, 2013, 9, e1003066.	1.5	30
44	Detection of Intracellular Factor VIII Protein in Peripheral Blood Mononuclear Cells by Flow Cytometry. BioMed Research International, 2013, 2013, 1-8.	0.9	7
45	Single-Nucleotide Variations Defining Previously Unreported ADAMTS13 Haplotypes Are Associated With Differential Expression and Activity Of The VWF-Cleaving Protease In a Salvadoran Congenital Thrombotic Thrombocytopenic Purpura Family. Blood, 2013, 122, 2319-2319.	0.6	0
46	Cyclosporin A Impairs the Secretion and Activity of ADAMTS13 (A Disintegrin and Metalloprotease with) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	12
47	Identification of sequenceâ€“structure RNA binding motifs for SELEX-derived aptamers. Bioinformatics, 2012, 28, i215-i223.	1.8	85
48	Mapping Conformational Changes Associated with the Catalytic Cycle of Human P-Glycoprotein (ABCB1). Biophysical Journal, 2012, 102, 606a-607a.	0.2	1
49	Aptamers as a Sensitive Tool to Detect Subtle Modifications in Therapeutic Proteins. PLoS ONE, 2012, 7, e31948.	1.1	35
50	Plasma derivatives: New products and new approaches. Biologicals, 2012, 40, 191-195.	0.5	8
51	Characterization of Coding Synonymous and Non-Synonymous Variants in ADAMTS13 Using Ex Vivo and In Silico Approaches. PLoS ONE, 2012, 7, e38864.	1.1	61
52	F8 and HLA-II Haplotypes in the Hispanic Population: Implications for Inhibitor Risk Development in Hispanic Hemophilia A Patients. Blood, 2012, 120, 3365-3365.	0.6	0
53	Secretion and Activity of ADAMTS13 Are Impaired by Cyclosporin A. Blood, 2012, 120, 3349-3349.	0.6	0
54	Common SNPs within or near Three Immune Response Genes Implicated in the Risk of FVIII Immunogenicity in Hemophilia A Do Not Influence Steady-State Levels of Their Encoded mRNAs. Blood, 2012, 120, 3366-3366.	0.6	0

#	Article	IF	Citations
55	Inhibition of Multidrug Resistance-Linked P-Glycoprotein (ABCB1) Function by 5â€²-Fluorosulfonylbenzoyl 5â€²-Adenosine: Evidence for an ATP Analogue That Interacts with Both Drug-Substrate-and Nucleotide-Binding Sites. Biochemistry, 2011, 50, 3724-3735.	1.2	13
56	Understanding the contribution of synonymous mutations to human disease. Nature Reviews Genetics, 2011, 12, 683-691.	7.7	815
57	Pharmacogenetics and the immunogenicity of protein therapeutics. Nature Biotechnology, 2011, 29, 870-873.	9.4	31
58	Single and Codon-Optimized Synonymous Mutations in Factor IX Alter Protein Properties. Blood, 2011, 118, 1185-1185.	0.6	0
59	The Entire Primary Sequence of Factor VIII Is Synthesized As Two Polypeptide Chains in Hemophilia A Patients with the Intron-22-Inversion. Blood, 2011, 118, 1176-1176.	0.6	1
60	The Signaling Interface of the Yeast Multidrug Transporter Pdr5 Adopts a Cis Conformation, and There Are Functional Overlap and Equivalence of the Deviant and Canonical Q-Loop Residues. Biochemistry, 2010, 49, 4440-4449.	1.2	41
61	The Synonymous V107V Mutation In Factor IX Is Not So Silent and May Cause Hemophilia B In Patients. Blood, 2010, 116, 2197-2197.	0.6	5
62	Detection of intracellular ADAMTS13, a secreted zincâ€metalloprotease, via flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2009, 75A, 675-681.	1.1	3
63	Silent (Synonymous) SNPs: Should We Care About Them?. Methods in Molecular Biology, 2009, 578, 23-39.	0.4	214
64	Characterization of Conformation-Sensitive Antibodies to ADAMTS13, the von Willebrand Cleavage Protease. PLoS ONE, 2009, 4, e6506.	1.1	12
65	Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima. Journal of Molecular Biology, 2008, 383, 281-291.	2.0	230
66	Mutations Define Cross-talk between the N-terminal Nucleotide-binding Domain and Transmembrane Helix-2 of the Yeast Multidrug Transporter Pdr5. Journal of Biological Chemistry, 2008, 283, 35010-35022.	1.6	60
67	The sounds of silence: synonymous mutations affect function. Pharmacogenomics, 2007, 8, 527-532.	0.6	47
68	About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Molecular Cancer Therapeutics, 2007, 6, 13-23.	1.9	132
69	Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of Cancer. Cancer Research, 2007, 67, 9609-9612.	0.4	219
70	A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity. Science, 2007, 315, 525-528.	6.0	2,230
71	Catalytic Cycle of ATP Hydrolysis by P-Glycoprotein:â€‰ Evidence for Formation of the EÂ·S Reaction Intermediate with ATP-Î³-S, a Nonhydrolyzable Analogue of ATP. Biochemistry, 2007, 46, 13787-13799.	1.2	95
72	Complete Inhibition of the Pdr5p Multidrug Efflux Pump ATPase Activity by Its Transport Substrate Clotrimazole Suggests that GTP as Well as ATP May Be Used as an Energy Source. Biochemistry, 2007, 46, 13109-13119.	1.2	52

#	Article	IF	Citations
73	Genomics and the mechanism of P-glycoprotein (ABCB1). Journal of Bioenergetics and Biomembranes, 2007, 39, 481-487.	1.0	76
74	The Conserved Tyrosine Residues 401 and 1044 in ATP Sites of Human P-Glycoprotein Are Critical for ATP Binding and Hydrolysis:â€‰ Evidence for a Conserved Subdomain, the A-Loop in the ATP-Binding Cassette. Biochemistry, 2006, 45, 7605-7616.	1.2	56
75	The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. FEBS Letters, 2006, 580, 1049-1055.	1.3	146
76	The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1). European Journal of Pharmaceutical Sciences, 2006, 27, 392-400.	1.9	196
77	Exploiting Reaction Intermediates of the ATPase Reaction to Elucidate the Mechanism of Transport by P-glycoprotein (ABCB1). Journal of Biological Chemistry, 2006, 281, 26501-26511.	1.6	39
78	Selective Toxicity of NSC73306 in MDR1-Positive Cells as a New Strategy to Circumvent Multidrug Resistance in Cancer. Cancer Research, 2006, 66, 4808-4815.	0.4	162
79	Nonequivalence of the Nucleotide Binding Domains of the ArsA ATPase. Journal of Biological Chemistry, 2005, 280, 9921-9926.	1.6	10
80	Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Molecular BioSystems, 2005, 1, 127.	2.9	90
81	A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1). Trends in Pharmacological Sciences, 2005, 26, 385-387.	4.0	86
82	Multidrug Resistance Protein 4 (ABCC4)-mediated ATP Hydrolysis. Journal of Biological Chemistry, 2004, 279, 48855-48864.	1.6	49
83	The Molecular Basis of the Action of Disulfiram as a Modulator of the Multidrug Resistance-Linked ATP Binding Cassette Transporters MDR1 (ABCB1) and MRP1 (ABCC1). Molecular Pharmacology, 2004, 65, 675-684.	1.0	91
84	Biochemical Basis of Polyvalency as a Strategy for Enhancing the Efficacy of P-Glycoprotein (ABCB1) Modulators:Â Stipiamide Homodimers Separated with Defined-Length Spacers Reverse Drug Efflux with Greater Efficacy. Biochemistry, 2004, 43, 2262-2271.	1.2	58
85	Mutational Analysis of ABCG2:â€‰ Role of the GXXXG Motif. Biochemistry, 2004, 43, 9448-9456.	1.2	96
86	Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans. Biochemical and Biophysical Research Communications, 2004, 322, 520-525.	1.0	53
87	P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.	2.6	956
88	Elf1p, a Member of the ABC Class of ATPases, Functions as a mRNA Export Factor in Schizosacchromyces pombe. Journal of Biological Chemistry, 2002, 277, 33580-33589.	1.6	22
89	Importance of the Conserved Walker B Glutamate Residues, 556 and 1201, for the Completion of the Catalytic Cycle of ATP Hydrolysis by Human P-glycoprotein (ABCB1). Biochemistry, 2002, 41, 13989-14000.	1.2	99